Skip to main content

Table 1 Patients' characteristics and treatment outcomes of previously untreated and relapsed/refractory multiple myeloma

From: Treatment outcome of thalidomide based regimens in newly diagnosed and relapsed/refractory non-transplant multiple myeloma patients: a single center experience from Thailand

Characteristics   ORR CR/VGPR PFS OS
Total patients (N = 42) No. of
Patients
%
p-value No. of
patients
p-value HR 95% CI p-value HR 95% CI p-value
Age (years), median (range) 62,(36-75)           
   ≤ 60 17 15(94) 0.83 9(56.3) 0.45 2.95 0.98-8.81 0.05 0.81 0.09-7.27 0.85
   > 60 25 23(92)   17(68)        
Sex            
   Male 21 18(85.7) 0.79 13(65) 0.91 0.77 0.25-2.38 0.65 2.06 0.34-12.68 0.44
   Female 21 20(95.2)   14(66.7)        
Prior treatment            
   Yes 29 26(92.6) 0.95 19(67.9) 0.69 3.68 0.91-10.28 0.06 0.87 0.96-7.88 0.9
   No 13 12(92.3)   8(61.5)        
International staging system            
   I, II 8, 18 24(92.3) 0.97 15(57.7) 0.93 6.30 0.73-54.01 0.09 2.22 0.20-24.57 0.51
   III 13 12(92.3)   8(61.5)        
   No data 3           
M-protein subtype            
   IgG, IgA, IgM 23, 8, 1 27(87.1) 0.32 19(61.3) 0.86 3.19 0.64-15.91 0.16 1.21 0.13-11.65 0.87
   Kappa, Lamda 3, 6 9(100)   6(66.7)        
   Unknown type 1           
Serum creatinine level            
   < 2 mg/dl 34 31(91.2) 0.43 22(64.7) 0.57 0.74 0.08-6.72 0.79 0.03 0.01-856.9 0.50
   ≥ 2 mg/dl 8 7(100)   4(57.2)        
Serum β2 M level, μg/ml            
   ≤ 5 26 24(92.3) 0.53 17(65.4) 0.79 4.89 0.55-43.88 0.16 1.97 0.18-21.81 0.58
   > 5 13 11(84.6)   8(61.5)        
   No data 3           
Response to treatment            
   Yes 38 - - - - 0.15 0.04-0.61 0.01 0.03 0.01-0.35 0.01
   No 3           
CR/VGPR            
   Yes 26 - - - - 0.14 0.04-0.47 0.01 0.21 0.03-1.48 0.12
   No 15